Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) CRO Marcus Jewell sold 12,562 shares of the firm’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $11.24, for a total value of $141,196.88. Following the completion of the sale, the executive directly owned 427,128 shares of the company’s stock, valued at $4,800,918.72. This trade represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Marcus Jewell also recently made the following trade(s):
- On Wednesday, August 12th, Marcus Jewell sold 411 shares of Cellebrite DI stock. The stock was sold at an average price of $16.07, for a total value of $6,604.77.
Cellebrite DI Price Performance
Shares of CLBT traded up $0.44 during mid-day trading on Monday, reaching $11.49. The stock had a trading volume of 3,463,245 shares, compared to its average volume of 2,270,829. Cellebrite DI Ltd. has a 52-week low of $9.58 and a 52-week high of $19.98. The business’s fifty day moving average is $14.27 and its 200 day moving average is $13.85. The firm has a market cap of $2.87 billion, a price-to-earnings ratio of 52.23, a P/E/G ratio of 1.53 and a beta of 1.18.
Institutional Trading of Cellebrite DI
Wall Street Analyst Weigh In
CLBT has been the topic of several analyst reports. DA Davidson reduced their price target on shares of Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. JPMorgan Chase & Co. cut their target price on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, August 14th. Lake Street Capital decreased their price target on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Weiss Ratings cut Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, August 13th. Finally, Needham & Company LLC cut their price objective on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research report on Friday, August 14th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.70.
Check Out Our Latest Stock Analysis on CLBT
About Cellebrite DI
Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.
The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.
Featured Articles
- Five stocks we like better than Cellebrite DI
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.
